



Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

<b>TRANSMITTAL FORM</b>		Application Number	10/686,619
		Filing Date	October 17, 2003
		First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
		Group Art Unit	1634
		Examiner Name	Jennifer Shin Shin Wong
Total Number of Pages in This Submission	5	Attorney Docket Number	031896-004000 (AM100990)

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment	<input type="checkbox"/> Declaration and Power of Attorney	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Application Data Sheet
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s):
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> CD, Number of CD(s) _____	
Remarks <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-004000) for the above identified docket number.		

**PTO Form-1449 citing two (2) U.S. patent, one (1) foreign patent and seventeen (17) non-patent literature documents, including one (1) International Search Report.**

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	<b>Raymond Van Dyke, Reg. No.34,746</b> Nixon Peabody LLP 409 9 <sup>th</sup> Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	October 12, 2005

### CERTIFICATE OF MAILING

#### CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
- transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.

Date \_\_\_\_\_

Signature \_\_\_\_\_



Docket No. 031896-004000  
(AM100990)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: )  
Margot Mary O'TOOLE et al. ) Group Art Unit: 1634  
Serial No.: 10/686,619 ) Examiner: Jennifer Shin Shin Wong  
Filed: October 17, 2003 ) Confirmation No.: 9490  
For: **COMPOSITIONS AND METHODS** )  
**FOR DIAGNOSING AND TREATING** )  
**AUTOIMMUNE DISEASE** )

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

The documents cited in the enclosed Form-PTO-1449 are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

In view of the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patent documents are not included with this Statement. However, copies of the cited foreign patent and non-patent literature documents, as well as the International Search Report from a related international patent application, are enclosed.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing,  
which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

By:   
Raymond Van Dyke  
Registration No. 34,746

Date: October 12, 2005

**NIXON PEABODY LLP**  
**Customer No. 50839**  
Suite 900  
401 9<sup>th</sup> Street, N.W.  
Washington, DC 20004-2128  
(202) 585-8000



Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/686,619
Sheet	1	of	2	Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Jennifer Shin Shin Wong
				Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> ( <i>if known</i> )			
		U.S. - 4,554,101	11-19-1985	HOPP, T. P.	
		U.S. - 2003/0148298 A1	08-07-2003	O'TOOLE, M. <i>et al.</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Kind Code <sup>2</sup> <i>(if known)</i>			
		WO 2004/036221 A2	04-29-2004	O'TOOLE <i>et al.</i>	T <sup>6</sup>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		FRAMPTON, G. <i>et al.</i> , Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen, <i>Rheumatology (Oxford)</i> , 39(10):1114-1120, 2000			
		ADACHI, M., <i>et al.</i> , Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer, <i>Cancer Res.</i> , 56(8):1751-1755, 1996			
		DUAN, J. <i>et al.</i> , Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis, <i>FEBS Lett.</i> , 499(1-2):127-132, 2001			
		HAMMOND, C. <i>et al.</i> , The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules, <i>J. Immunol.</i> , 161(7):3282-3291, 1998			
		HECKENLIVELY, J. R. <i>et al.</i> , Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration, <i>Arch. Ophthalmol.</i> , 118(2):1525-1533, 2000			
		LAGAUDRIERE-GESBERT, C. <i>et al.</i> , The tetraspanin protein CD82 associates with both free HLA class I heavy chain and heterodimeric beta 2-microglobulin complexes, <i>J. Immunol.</i> , 158(6):2790-2797, 1997			
		LEBEL-BINAY, S. <i>et al.</i> , CD82, member of the tetra-span-transmembrane protein family, is a costimulatory protein for T cell activation, <i>J. Immunol.</i> , 155(1):101-110, 1995			
		MAEDA, A. <i>et al.</i> , Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice, <i>Eur. J. Immunol.</i> , 32:2300-2307, 2002			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Jennifer Shin Shin Wong
Sheet	2	of	2	Attorney Docket Number	031896-004000 (AM100990)
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		ROTH, W. <i>et al.</i> , Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells, <i>Oncogene</i> , 19(37):4210-4220, 2000			
		XU, N. <i>et al.</i> , Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells, <i>Biochem. Biophys. Res. Commun.</i> , 292(4):944-950, 2002			
		XU, N. <i>et al.</i> , A novel human apolipoprotein (apoM), <i>J. Biol. Chem.</i> , 274(44):31286-31290, 1999			
		YOSHINO, K. <i>et al.</i> , Secreted Frizzled-related proteins can regulate metanephric development, <i>Mech. Dev.</i> , 102(1-2):45-55, 2001			
		LEE, N. S. <i>et al.</i> , Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, <i>Nat. Biotechnol.</i> , 20(5):500-505, 2002			
		BAZHIN, A. V. <i>et al.</i> , Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision, <i>Lung Cancer</i> , 34(1):99-104, 2001			
		International Search Report for International Application No. PCT/US2004/005655, mailed November 8, 2004, 6 sheets			
		ROZZO, S. J. <i>et al.</i> , Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus, <i>Immunity</i> , 15(3): 435-443, 2001			
		MOSER, K. L. <i>et al.</i> , The use of microarrays to study autoimmunity, <i>J. Investig. Dermatol. Symp. Proc.</i> , 9(1):18-22, 2004			
		BENNETT, L. <i>et al.</i> , Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, <i>J. Exp. Med.</i> , 97(6):711-723, 2003			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.